These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8024657)

  • 21. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.
    Schellens JH; Planting AS; van Acker BA; Loos WJ; de Boer-Dennert M; van der Burg ME; Koier I; Krediet RT; Stoter G; Verweij J
    J Natl Cancer Inst; 1994 Jun; 86(12):906-12. PubMed ID: 8196081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
    Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for antitumor agents].
    Inaba M
    Gan To Kagaku Ryoho; 1991 Jul; 18(9):1449-56. PubMed ID: 1906701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.
    Rinaldi DA; Kuhn JG; Burris HA; Dorr FA; Rodriguez G; Eckhardt SG; Jones S; Woodworth JR; Baker S; Langley C; Mascorro D; Abrahams T; Von Hoff DD
    Cancer Chemother Pharmacol; 1999; 44(5):372-80. PubMed ID: 10501910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
    Campone M; Isambert N; Bourbouloux E; Maury S; Monin-Baroille P; Berille J; Fumoleau P
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):689-95. PubMed ID: 17031647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patients.
    Davis LE; Alberts DS; Plezia PM; Roe DJ; Griswold DP
    J Natl Cancer Inst; 1988 Aug; 80(11):815-9. PubMed ID: 3392741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interspecies scaling of maximum tolerated dose of anticancer drugs: relevance to starting dose for phase I clinical trials.
    Mahmood I
    Am J Ther; 2001; 8(2):109-16. PubMed ID: 11304664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
    J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
    Le Tourneau C; Stathis A; Vidal L; Moore MJ; Siu LL
    J Clin Oncol; 2010 Mar; 28(8):1401-7. PubMed ID: 20124167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics and dose optimisation of carboplatin.
    Duffull SB; Robinson BA
    Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
    Puchalski TA; Ryan DP; Garcia-Carbonero R; Demetri GD; Butkiewicz L; Harmon D; Seiden MV; Maki RG; Lopez-Lazaro L; Jimeno J; Guzman C; Supko JG
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):309-19. PubMed ID: 12357306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens.
    Jordan SD; Poole CJ; Archer VR; Steven NM; Burton A
    Cancer Chemother Pharmacol; 2003 Aug; 52(2):113-8. PubMed ID: 12783201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individual dose adaptation of anticancer drugs.
    Desoize B; Robert J
    Eur J Cancer; 1994; 30A(6):844-51. PubMed ID: 7917547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Animal toxicology for early clinical trials with anticancer agents.
    Rozencweig M; Von Hoff DD; Staquet MJ; Schein PS; Penta JS; Goldin A; Muggia FM; Freireich EJ; DeVita VT
    Cancer Clin Trials; 1981; 4(1):21-8. PubMed ID: 6783332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers.
    Gelmon K; Hirte H; Fisher B; Walsh W; Ptaszynski M; Hamilton M; Onetto N; Eisenhauer E
    Invest New Drugs; 2004 Aug; 22(3):263-75. PubMed ID: 15122073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
    Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.